These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37771774)

  • 1. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
    Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
    Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
    Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
    Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.
    Zaidi AH; Kelly RJ; Gorbunova A; Omstead AN; Salvitti MS; Zheng P; Kosovec JE; Lee S; Ayazi S; Babar L; Finley GG; Goel A; Jobe BA
    Oncotarget; 2021 Feb; 12(4):292-303. PubMed ID: 33659041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
    Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
    Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
    Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
    Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
    Front Oncol; 2021; 11():621550. PubMed ID: 33777767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
    Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ
    J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
    Shi F; Su J; Wang J; Liu Z; Wang T
    Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer.
    Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.